The estimated Net Worth of Christopher J Twomey is at least $5.93 Million dollars as of 22 May 2024. Mr. Twomey owns over 4,434 units of Tandem Diabetes Care Inc stock worth over $482,336 and over the last 11 years he sold TNDM stock worth over $5,234,777. In addition, he makes $216,966 as Independent Director at Tandem Diabetes Care Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Twomey TNDM stock SEC Form 4 insiders trading
Christopher has made over 15 trades of the Tandem Diabetes Care Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 4,434 units of TNDM stock worth $229,371 on 22 May 2024.
The largest trade he's ever made was buying 75,000 units of Tandem Diabetes Care Inc stock on 9 February 2018 worth over $150,000. On average, Christopher trades about 3,385 units every 56 days since 2013. As of 22 May 2024 he still owns at least 11,288 units of Tandem Diabetes Care Inc stock.
You can see the complete history of Mr. Twomey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Twomey biography
Christopher J Twomey is an Independent Director of Tandem Diabetes Care Inc. Mr. Twomey has served on our board of directors since July 2013. Mr. Twomey has served as a director and chair of the audit committee of Bionano Genomics (NASDAQ: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey also served as a director and chair of the audit committee of Senomyx, Inc., a flavor technology company, from March 2006 until its sale to Firmenich SA in November 2018. He also served as a director and chair of the audit committee of Cadence Pharmaceuticals, Inc., from July 2006 until it was acquired by Mallinckrodt plc in March 2014. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.
What is the salary of Christopher Twomey?
As the Independent Director of Tandem Diabetes Care Inc, the total compensation of Christopher Twomey at Tandem Diabetes Care Inc is $216,966. There are 15 executives at Tandem Diabetes Care Inc getting paid more, with John Sheridan having the highest compensation of $10,560,900.
How old is Christopher Twomey?
Christopher Twomey is 60, he's been the Independent Director of Tandem Diabetes Care Inc since 2013. There are 5 older and 17 younger executives at Tandem Diabetes Care Inc. The oldest executive at Tandem Diabetes Care Inc is Dick Allen, 75, who is the Lead Independent Director.
What's Christopher Twomey's mailing address?
Christopher's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.
Insiders trading at Tandem Diabetes Care Inc
Over the last 11 years, insiders at Tandem Diabetes Care Inc have traded over $154,253,951 worth of Tandem Diabetes Care Inc stock and bought 4,118,443 units worth $11,618,906 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Douglas A Roeder, and Nicole Vitullo. On average, Tandem Diabetes Care Inc executives and independent directors trade stock every 9 days with the average trade being worth of $885,878. The most recent stock trade was executed by Shannon Marie Hansen on 15 August 2024, trading 1,968 units of TNDM stock currently worth $84,093.
What does Tandem Diabetes Care Inc do?
tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan
What does Tandem Diabetes Care Inc's logo look like?
Complete history of Mr. Twomey stock trades at Tandem Diabetes Care Inc and Bionano Genomics Inc
Tandem Diabetes Care Inc executives and stock owners
Tandem Diabetes Care Inc executives and other stock owners filed with the SEC include:
-
John Sheridan,
President, Chief Executive Officer, Director -
Kim Blickenstaff,
Chairman of the Board -
Brian Hansen,
Chief Commercial Officer, Executive Vice President -
Leigh Vosseller,
Chief Financial Officer, Executive Vice President, Treasurer -
David Berger,
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary -
Susan Morrison,
Executive Vice President, Chief Administrative Officer -
Rebecca Robertson,
Independent Director -
John F. Sheridan,
Pres, CEO & Director -
David B. Berger Esq.,
Exec. VP & COO -
Elizabeth Anne Gasser,
Exec. VP & Chief Strategy Officer -
Brian B. Hansen,
Exec. VP & Chief Commercial Officer -
Leigh A. Vosseller,
Exec. VP, CFO & Treasurer -
David B. Berger,
Exec. VP, Chief Bus. Operations & Compliance Officer and Corp. Sec. -
Susan M. Morrison,
Exec. VP & Chief Admin. Officer -
Dick Allen,
Lead Independent Director -
Christopher Twomey,
Independent Director -
Douglas Roeder,
Independent Director -
Edward Cahill,
Independent Director -
Peyton Howell,
Independent Director -
Kathleen McGroddy-Goetz,
Independent Director -
Elizabeth Gasser,
Executive Vice President - Strategy and Corporate Development -
Shannon M. Hansen,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Manuel Jaime,
Sr. VP of Technology & Digital Health -
Tom Fox,
Sr. VP of HR & Organizational Devel. -
Ross Sylvia,
VP of Marketing -
Rick Carpenter,
Chief Technical Officer -
Jim Leal,
Sr. VP of Operations -
Richard P. Valencia,
Director -
Jesse I Treu,
Director -
Howard E Jr Greene,
Director -
Fred E Cohen,
Director -
Lonnie M Smith,
Director -
Henry Anhalt,
Director -
John Cajigas,
CHIEF FINANCIAL OFFICER -
Management Partners Viii, L...,
-
Venture Partners Ii, L.P.Hl...,
-
Group Holdings (Sbs) Adviso...,
-
Parters Vii L P Domain,
10% owner -
Nicole Vitullo,
10% owner -
Kathleen K Schoemaker,
10% owner -
Brian K Halak,
10% owner -
Robert Anacone,
EXECUTIVE VP AND CCO -
Brian H Dovey,
10% owner -
James C Blair,
10% owner -
Vii Associates Lp Dp,
10% owner -
Jean Claude Kyrillos,
EVP & Chief Operating Officer -
Rajwant Sodhi,
Director -
James Leal,
Chief Manufacturing Officer -
Shannon Marie Hansen,
EVP & Chief Legal Officer -
Myoungil Cha,
Director -
Joao Paulo Falcao Malagueira,
Director -
Mark David Novara,
EVP & CHIEF COMMERCIAL OFFICER -
Rick Carpenter,
Chief Technology Officer